Identification of the neuritogen for experimental allergic neuritis.
about
The three-dimensional structure of P2 myelin proteinDimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal ProtectionA general model of the P2 protein of peripheral nervous system myelin based on secondary structure predictions, tertiary folding principles, and experimental observations.Bovine peripheral nervous system myelin P2 protein: chemical and immunological characterization of the cyanogen bromide peptides.Peripheral nerve protein expression and carbonyl content in N,N-diethlydithiocarbamate myelinopathyFingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protectionThe role of chemokines in Guillain-Barré syndrome.Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitopeNovel therapeutic approaches to Guillain-Barré syndrome.Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.The complete amino acid sequence of human P2 protein.T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.Immunohistochemical localization of S-100 protein and peripheral nerve myelin proteins (P2 protein, P0 protein) in granular cell tumors.Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.Production of tumor necrosis factor and other proinflammatory cytokines by human mononuclear phagocytes stimulated with myelin P2 proteinExperimental autoimmune peripheral neuritis induced in BALB/c mice by myelin basic protein-specific T cell clones.The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.Guillain-Barré syndrome: a century of progress.Reciprocal relationship between membrane type 1 matrix metalloproteinase and the algesic peptides of myelin basic protein contributes to chronic neuropathic pain.Immune responses in experimental allergic neuritis.Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Immune mechanisms in inflammatory polyneuropathy.Role of TNF-alpha in high-dose antigen therapy in experimental autoimmune neuritis: inhibition of TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis.Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl.Spontaneous and experimental neuritis and the distribution of the myelin protein P2 in the nervous system.Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis.Neuritogenic determinant of bovine P2 protein in peripheral nerve myelin.A sensitive and selective ELISA methodology quantifies a demyelination marker in experimental and clinical samples.Treatment for experimental autoimmune neuritis with clodronate (Bonefos).Capsaicin-enriched diet ameliorates autoimmune neuritis in rats.Administration of SB203580, a p38 MAPK Inhibitor, Reduced the Expression of MMP9, and Relieved Neurologic Severity in the Experimental Autoimmune Neuritis (EAN) in Rats.STRUCTURAL AND FUNCTIONAL STUDIES OF VITAMIN A-BINDING PROTEINS
P2860
Q24563728-95749453-71FD-4FB9-9FA9-23C514F0A5E3Q28551190-9C06A633-7C96-453B-9B27-0836EE725291Q30196332-4E62F7B7-F32E-4136-8211-77A88E6F1191Q30411990-73243F5C-D8DD-4260-B97F-FF00D313E755Q33275555-C81D4760-3C5F-467C-BE81-8782A87B4C15Q33608864-EAB6E86B-66C8-4F79-B1B8-ED1C20A3ECFAQ33624382-DFA6AC7F-CCBA-468F-92B0-7637B8358279Q33950157-078338F6-CA59-4C04-B47A-6C6732AC2926Q34075115-9392B2D2-D018-43B0-BD65-64973A2A443FQ34109136-46363B32-A19C-428B-A15B-AEB2853DE55DQ34249637-7E7CAD63-113F-43E5-A8AD-43C3A085AFB2Q35484496-02F94AB8-CB72-4AF8-AAD8-B92E542498DEQ35885680-4599951F-D824-485E-A545-A91B34AF3A5DQ35996437-EB2B5398-9945-4D60-B08B-FCF59051753CQ36005389-FA4E61D9-25DE-4D2B-810D-245532BFADECQ36297620-C171EE33-F006-42B8-AC37-68F2CD624648Q36365293-A2C0BD42-9F20-4D06-AE4C-A167EBA330B8Q37828450-776B9A11-7AAD-4FBE-AC90-313C4396F11CQ39011456-680BD9A9-E17B-42CE-B041-03A880E4D070Q39197809-511B0406-B9C5-441A-9F56-4A9FC827189EQ39253099-5BC0B96E-362C-49F8-99D6-9A615834C1A9Q39434973-A39ABFA6-550A-4C79-A95F-89E8EDD7D2C0Q39607874-028826C4-5F56-408D-9142-C9D9AF8F2352Q40869266-C19DC43F-278E-4795-86CB-1B744A9ABEFEQ43046804-85CD3914-DB70-4519-BB24-A431352EF291Q48694606-F5F235C3-D22E-4EFB-810D-3E4B5CF563DCQ48863768-9418CAB4-FED2-4B9C-9357-0A45ECF1A62BQ48908520-E8C80562-58D7-4AC1-A627-6507667142B4Q50049037-46F6A3F7-9C91-4E12-9981-101C1E951DD4Q51072939-18ABF892-AA5D-4102-A7BE-AA117B86DC6AQ52565808-77937BED-2BDF-4F0D-9850-1E56CF6694B5Q53496273-49A4CABC-C015-40CD-905A-8CD3DF0CBFAFQ56591786-A03EA81B-7882-4EC6-8180-86698DFBF761
P2860
Identification of the neuritogen for experimental allergic neuritis.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Identification of the neuritogen for experimental allergic neuritis.
@en
type
label
Identification of the neuritogen for experimental allergic neuritis.
@en
prefLabel
Identification of the neuritogen for experimental allergic neuritis.
@en
P2860
P356
P1433
P1476
Identification of the neuritogen for experimental allergic neuritis.
@en
P2093
Kadlubowski M
P2860
P2888
P304
P356
10.1038/277140A0
P407
P577
1979-01-01T00:00:00Z
P6179
1051031005